Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2000
04/12/2000CN1250375A Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
04/12/2000CN1250369A Method of treating dry eye disease with purinergic receptor agonists
04/11/2000US6048970 Prostate growth-associated membrane proteins
04/11/2000US6048967 Blood compound associated with a nitroxide compound to prevent or alleviate the side effects of oxygen stress
04/11/2000US6048963 Polynucleotides and polypeptides associated with benign prostatic hypertrophy
04/11/2000US6048891 Administering mixtures with 6-hydroxy-2,7,8-trimethyl-chroman-2-propanoic acid for treatment of cardiovascular and kidney disorders
04/11/2000US6048872 Dietetics; antidiabetic agents; cardiovascular disorders; gastrointestinal disorders
04/11/2000US6048858 Heteroring containing a sulfonamide group
04/11/2000US6048852 Bactericides
04/11/2000US6048849 Mixture of hormone or hormone inhibitor and sulfur containing compound
04/11/2000US6048846 Syergistic mixture of hormone, amino acid, enzyme and mineral
04/11/2000US6048844 Treatment of conditions and disease
04/11/2000US6048843 Topical composition containing amino acid in combination with either interferon of thymidine derivatives for treating viral or inflammation diseases
04/11/2000US6048716 Microorganism polypeptide; for infection prevention bactericides; wound healing agents
04/11/2000US6048709 Polynucleotide sequence coding a endothelial marker polypeptide; for the detection and therapy of heart and vascular disorders
04/11/2000US6048698 Producing products by bond formation of a reactant bound to nucleic acid and a free reactant, then contacting product library with target to partition products by ability to perform preselected function
04/11/2000US6048541 Fast-dissolving comestible units formed under high-speed/high-pressure conditions
04/06/2000WO2000019210A2 Determining the mechanism of beta-amyloid peptide generation
04/06/2000WO2000019206A1 Ykl-40 as a marker and prognostic indicator for cancers
04/06/2000WO2000019200A1 Identifying agents that alter mitochondrial permeability transition pores
04/06/2000WO2000018961A2 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
04/06/2000WO2000018959A1 Trex, a novel gene of traf-interacting ext gene family and diagnostic and therapeutic uses thereof
04/06/2000WO2000018954A2 Use of pex in the treatment of metabolic bone diseases
04/06/2000WO2000018952A1 Use of s-ydcb and b-ydcb, essential bacterial genes
04/06/2000WO2000018923A2 Slgp protein and nucleic acid molecule and uses therefor
04/06/2000WO2000018919A1 Human kinesin-like motor protein
04/06/2000WO2000018917A2 α-SYNUCLEIN SUPER-MUTANTS ACCELERATE α-SYNUCLEIN AGGREGATION
04/06/2000WO2000018915A2 Membrane-associated organizational proteins
04/06/2000WO2000018912A2 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
04/06/2000WO2000018899A2 Angiotensin converting enzyme homolog and its use
04/06/2000WO2000018885A1 Methods of controlling proliferation and differentiation of stem and progenitor cells
04/06/2000WO2000018835A1 Modified starch film compositions
04/06/2000WO2000018821A1 Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties
04/06/2000WO2000018801A2 Ncam binding compounds
04/06/2000WO2000018797A1 Map
04/06/2000WO2000018794A1 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
04/06/2000WO2000018749A1 Indeno-, naphto- and benzocyclohepta dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
04/06/2000WO2000018438A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof
04/06/2000WO2000018436A1 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
04/06/2000WO2000018432A1 Carbohydrate vaccines for viral diseases
04/06/2000WO2000018424A1 Use of substances with oxytocin activity in order to create cell regeneration
04/06/2000WO2000018409A1 Use of certain drugs for treating nerve root injury
04/06/2000WO2000018405A1 Use of prostanoid antagonists for the treatment of primary headache disorders
04/06/2000WO2000018402A1 Method for treating androgen-related conditions
04/06/2000WO2000018398A1 Pharmaceutically active compounds and methods of use thereof
04/06/2000WO2000018395A1 Method for preventing or delaying catheter-based revascularization
04/06/2000WO2000018393A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
04/06/2000WO2000018391A1 Drugs for improving vesical excretory strength
04/06/2000WO2000018388A2 Antibiotic compositions for treatment of the eye, ear and nose
04/06/2000WO2000018386A2 Antibiotic compositions for treatment of the eye, ear and nose
04/06/2000WO2000018371A1 Proteinic drug delivery system using membrane mimetics
04/06/2000WO2000018370A2 Liquid pharmaceutical for oral delivery
04/06/2000WO2000018365A2 Fast dissolving orally consumable films
04/06/2000WO2000018352A2 A method for treating inflammatory diseases by administering a thrombin inhibitor
04/06/2000WO2000018316A2 Sustained release, and comfortable ophthalmic composition and method for ocular therapy
04/06/2000WO2000018234A1 Thiazolidenediones alone or in combination with other therapeutic agents for tumor therapy
04/06/2000WO2000018231A1 Methods for treating or preventing viral infections and associated diseases
04/06/2000WO2000018212A2 Platelet-derived growth factor c, dna coding therefor, and uses thereof
04/06/2000WO2000001400A9 Compositions comprising endotoxin neutralizing protein and derivatives and uses thereof
04/06/2000WO1999067384A3 Prostate cancer-associated genes
04/06/2000WO1999066936A9 Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
04/06/2000WO1999064596A3 Proteins regulating gene expression
04/06/2000WO1999062505A3 Method for treating neurodegenerative disorders
04/06/2000WO1999061618A3 Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
04/06/2000WO1999061468A3 The induction of antibiotic peptides by lait (scd14) protein
04/06/2000WO1999061453A3 priA
04/06/2000WO1999061013A3 COMPOUNDS HAVING IgE AFFECTING PROPERTIES
04/06/2000WO1999059608A3 Osteoporosis treatment
04/06/2000WO1999058162A3 Pharmaceuticals for the imaging of angiogenic disorders
04/06/2000WO1999057144A3 Human transcriptional regulator molecules
04/06/2000WO1999054706A3 Method of treating interstitial cystitis with recombinant hb-egf
04/06/2000WO1999052858A3 Lipids
04/06/2000WO1999046284A3 Molecules that home to various selected organs or tissues
04/06/2000WO1999045907A3 Metal chelators for use in the treatment of alzheimer's disease
04/06/2000CA2794705A1 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
04/06/2000CA2774207A1 Antibiotic compositions for treatment of the eye
04/06/2000CA2714449A1 Use of certain drugs for treating nerve root injury
04/06/2000CA2659064A1 Antibiotic compositions for treatment of the ear and nose
04/06/2000CA2346061A1 Carbohydrate vaccines for viral diseases
04/06/2000CA2345641A1 A method for treating inflammatory diseases by administering a thrombin inhibitor
04/06/2000CA2345359A1 Indeno-, naphto- and benzocyclohepta dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
04/06/2000CA2345347A1 Methods for treating or preventing viral infections and associated diseases
04/06/2000CA2345273A1 Pharmaceutically active compounds and methods of use thereof
04/06/2000CA2345075A1 Mixed liposome drug delivery system using membrane mimetics
04/06/2000CA2345066A1 Identifying agents that alter mitochondrial permeability transition pores
04/06/2000CA2344894A1 Agents for improving excretory potency of urinary bladder
04/06/2000CA2344658A1 Human kinesin-like motor protein
04/06/2000CA2344653A1 Methods of controlling proliferation and differentiation of stem and progenitor cells
04/06/2000CA2344561A1 Platelet-derived growth factor c, dna coding therefor, and uses thereof
04/06/2000CA2344550A1 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
04/06/2000CA2344457A1 Slgp protein and nucleic acid molecule and uses therefor
04/06/2000CA2344292A1 Modified starch film compositions
04/06/2000CA2344274A1 Angiotensin converting enzyme homolog and its use
04/06/2000CA2344107A1 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
04/06/2000CA2343975A1 Ncam binding compounds
04/06/2000CA2343972A1 Ykl-40 as a marker and prognostic indicator for cancers
04/06/2000CA2343965A1 Use of s-ydcb and b-ydcb, essential bacterial genes
04/06/2000CA2343929A1 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
04/06/2000CA2343696A1 Membrane-associated organizational proteins
04/06/2000CA2343656A1 Trex, a novel gene of traf-interacting ext gene family and diagnostic and therapeutic uses thereof
1 ... 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 ... 1151